Bernstein analyst Lee Hambright raised the firm’s price target on Medtronic (MDT) to $111 from $98 and keeps an Outperform rating on the shares. The firm notes the company delivered better than expected performance on both sales and adjusted EPS. Management is committed to ensuring investment in growth drivers and delivering earnings leverage, Bernstein adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic’s Strategic Growth and Cautious Optimism Amid Fiscal Gains and Investment Needs
- Medtronic Reports Strong Q2 2026 Financial Results
- Medtronic upgraded to Neutral from Sell at Goldman Sachs
- Medtronic’s Earnings Call Highlights Strong Growth and Raised Guidance
- Medtronic price target raised to $117 from $107 at Morgan Stanley